Abstract
Ion channels are involved in a large variety of cellular processes including stem cell differentiation. Numerous families of ion channels are present in the organism which can be distinguished by means of, for example, ion selectivity, gating mechanism, composition, or cell biological function. To characterize the distinct expression of this group of ion channels we have compared the mRNA expression levels of ion channel genes between human keratinocyte-derived induced pluripotent stem cells (hiPSCs) and their somatic cell source, keratinocytes from plucked human hair. This comparison revealed that 26% of the analyzed probes showed an upregulation of ion channels in hiPSCs while just 6% were downregulated. Additionally, iPSCs express a much higher number of ion channels compared to keratinocytes. Further, to narrow down specificity of ion channel expression in iPS cells we compared their expression patterns with differentiated progeny, namely, neurons and cardiomyocytes derived from iPS cells. To conclude, hiPSCs exhibit a very considerable and diverse ion channel expression pattern. Their detailed analysis could give an insight into their contribution to many cellular processes and even disease mechanisms.
1. Introduction
Ion channels are comprised of a large variety of differing families of pore proteins. Initially, ion channels were mostly known for their role in the nervous system where they play a crucial role in the signal transmission over neurites and synapses. But in fact they are involved in numerous other cellular processes including cell size regulation, muscle contractions, immune system activation [1], or hormone release [2]. Distinct ion channels are furthermore recognized to be of high importance for excitable cells of the heart: cardiomyocytes of the working myocardium as well as cells of the cardiac conduction system. In the heart, specific ion channels are responsible, for example, for the regulated generation of action potentials and for cardiac muscle contraction strength and time [3]. Additionally, ion channels play an important role in several differentiation and maturation processes [4–6]. The presented study aims to take a closer look at ion channel expression in human-induced pluripotent stem cells (hiPSCs) to give a start point for further analyses of their distinct roles at an early developmental cell state and differentiation processes.
hiPSCs are generated from somatic cells by timed overexpression of specific transcription factors and strongly resemble pluripotent embryonic stem cells [7, 8]. Pluripotency is amongst others defined by the ability to differentiate into cells of all three germ layers and unlimited symmetrical cell division. This cell system is widely utilized for studies investigating developmental processes or disease mechanisms [9, 10]. Although it has become clear that differentiation processes influence ion channel expression [11], the distinct role of ion channels during these processes is so far only poorly understood. Nevertheless, it became evident that certain ion channels play a pivotal role in stem cell biology, including cell fate determination, cell cycle regulation, or cytoskeletal reorganization [6, 12–15].
The possibilities of iPSCs include the generation of individual or patient-specific-pluripotent cells, which can be subsequently differentiated into the affected cell types. This is already utilized to study pathomechanisms in a variety of tissues and cell types [9, 16–18]. The so-called channelopathies which are based on mutations in ion channels are the cause of developmental disorders and are the subject of various studies [19, 20]. To elucidate the role of ion channels in cell differentiation, maturation or their role in pathomechanisms a well-founded knowledge of ion channel distribution in pluripotent cells, representing one of the earliest stages of development, is indispensable. In that respect, we compared the expression levels of several ion channels in human keratinocytes with their reprogrammed progeny, hiPSCs. Keratinocytes derived from plucked human hair [21, 22] represent one of the most promising cell sources for the generation of the investigated hiPSCs [23]. We have elucidated ion channel regulation for various channel families and their subtypes. Additionally, we compared the expression levels of ion channel families and subtypes, found to be regulated during reprogramming, with iPSC-differentiated progeny, namely, neurons and cardiomyocytes. These comparisons could be a start point to evaluate the contribution and function of different ion channels, for example, for self-renewal and differentiation processes in stem cells.
2. Material and Methods
2.1. Ethical Statement and Donor Information
After informed consent was given by the donors (ethical agreement by the University of Ulm, number 88/12) hair with intact hair roots was gathered by plucking from the scalp after desinfection. We used hair from healthy volunteers (age between 24 to 45 and both male and female gender).
2.2. hiPSC Generation and Cell Culture
Keratinocytes were obtained from plucked human scalp hair as already described [22]. Keratinocytes were propagated in EpiLife medium with HKGS supplement (both Invitrogen, Carlsbad, CA, USA). hiPSCs were generated from keratinocytes by lentiviral transduction of four reprogramming factors (Oct4, Sox2, Klf4, and cMyc) as described earlier [23]. After the reprogramming on rat embryonic fibroblasts they were maintained feeder-free on Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) coated dishes in mTeSR1 medium (Stemcell Technologies, Vancouver, CA, USA).
2.3. Gene Expression Microarrays
Gene expression microarrays were performed for 6 keratinocyte samples and 9 hiPSC samples with the Agilent Whole Human Genome Microarray Kit (4x44k microarray kit G4112F, Agilent Technologies, Santa Clara, CA, USA). 500 ng of total RNA was used to produce Cy3-CTP-labeled cRNA with the Agilent Low RNA Input Liner Amplification Kit. The cRNA was purified and 1,65 μg per array was hybridized for 17 h at 65°C and 10 r.p.m. Afterwards, the arrays were washed with Agilent Gene Expression Wash Buffers one and two and finally with acetonitrile for 1 min. The slides were scanned using Scan Control 7.0 software with a resolution of 5 μm. Scan data was extracted with the Feature Extraction 9.1 software. Expression levels were background adjusted and quantile normalized with the GeneSpring GX 12 software. Differential expression between keratinocytes and hiPSCs was analyzed using student's t-test. A fold change > 2 and a P value < 0.05 was considered significant and highlighted bold (upregulation) or italic (downregulation) in the results table. For comparisons of iPSCs with iPSC-derived neurons published data from GSE34879 (GSM856936, GSM856937, GSM856915, GSM856916) and for cardiomyocytes GSE17579 (GSM438022, GSM438026, GSM438034, GSM438021, GSM438032, GSM438036) were used (both from NCBI Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/geo/). Fold change is shown if >2.
3. Results
3.1. Differential Expression of Ion Channels in hiPSCs Compared to Keratinocytes
We first compared the expression of various ion channel families from keratinocytes to hiPSCs and from hiPSCs to cardiomyocytes and neurons, respectively. From the 387 probes (Table 1) binding in ion channel genes from parental keratinocytes to hiPSCs, 101 (26%) showed a significant increase in expression (fold change > 2, P < 0.05; labeled in bold) while 23 (6%) showed a significant decrease (fold change > −2, P < 0.05; labeled in italic). In a second step differentially regulated ion channels from hiPSCs to hiPSC-derived neurons were investigated and we found 29 ion channel transcripts to be upregulated (fold change > 2; labeled in bold) while 6 showed a significant decrease (fold change > −2; labeled in italic). For cardiomyocytes, mRNA levels of only 7 ion channel members were upregulated (fold change > 2; labeled in bold) and 10 mRNA levels showed a significant decrease (fold change > −2; labeled in italic).
Table 1.
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit, transcript variant 1 | NM_000068 | CACNA1A | 2.26E − 01 | −1.32 | ||
Calcium channel, voltage-dependent, N type, alpha 1B subunit | NM_000718 | CACNA1B | 7.27E − 01 | −1.10 | ||
Calcium channel, voltage-dependent, N type, alpha 1B subunit [Source: HGNC Symbol; Acc: 1389] | ENST00000277550 | CACNA1B | 7.15E − 01 | −1.14 | ||
Calcium channel, voltage-dependent, N type, alpha 1B subunit | NM_000718 | CACNA1B | 6.32E − 09 | 6.82 | ||
Calcium channel, voltage-dependent, N type, alpha 1B subunit [Source: HGNC Symbol; Acc: 1389] | ENST00000277551 | CACNA1B | 3.32E − 02 | −1.57 | ||
Calcium channel, voltage-dependent, L type, alpha 1C subunit, transcript variant 18 | NM_000719 | CACNA1C | 6.77E − 02 | −1.37 | ||
Calcium channel, voltage-dependent, L type, alpha 1C subunit, transcript variant 18 | NM_000719 | CACNA1C | 5.72E − 03 | 2.37 | 2.94 | |
Calcium channel, voltage-dependent, L type, alpha 1D subunit, transcript variant 1 | NM_000720 | CACNA1D | 3.83E − 01 | 1.58 | ||
Calcium channel, voltage-dependent, R type, alpha 1E subunit, transcript variant 3 | NM_000721 | CACNA1E | 3.10 E−02 | −4.48 | 2.08 | |
Calcium channel, voltage-dependent, R type, alpha 1E subunit [Source: HGNC Symbol; Acc: 1392] | ENST00000524607 | CACNA1E | 8.83E − 01 | 1.05 | ||
Calcium channel, voltage-dependent, L type, alpha 1F subunit | NM_005183 | CACNA1F | 8.92E − 01 | 1.02 | ||
Calcium channel, voltage-dependent, T type, alpha 1G subunit, transcript variant 15 | NM_198397 | CACNA1G | 6.42E − 01 | −1.12 | 4.60 | |
Calcium channel, voltage-dependent, T type, alpha 1G subunit, transcript variant 1 | NM_018896 | CACNA1G | 5.37E − 07 | 6.96 | ||
Calcium channel, voltage-dependent, T type, alpha 1H subunit, transcript variant 1 | NM_021098 | CACNA1H | 7.38E − 10 | 6.78 | ||
Calcium channel, voltage-dependent, T type, alpha 1I subunit, transcript variant 1 | NM_021096 | CACNA1I | 2.22E − 11 | 37.25 | ||
Calcium channel, voltage-dependent, T type, alpha 1I subunit, transcript variant 1 | NM_021096 | CACNA1I | 7.56E − 02 | −1.56 | ||
Calcium channel, voltage-dependent, L type, alpha 1S subunit | NM_000069 | CACNA1S | 5.22E − 02 | −1.97 | ||
Calcium channel, voltage-dependent, alpha 2/delta subunit 1 | NM_000722 | CACNA2D1 | 1.38E − 09 | 9.65 | ||
Calcium channel, voltage-dependent, alpha 2/delta subunit 2, transcript variant 1 | NM_001005505 | CACNA2D2 | 3.30E − 10 | 62.50 | 2.02 | |
Calcium channel, voltage-dependent, alpha 2/delta subunit 3 | NM_018398 | CACNA2D3 | 5.14E − 05 | 5.42 | 2.55 | |
Calcium channel, voltage-dependent, alpha 2/delta subunit 3 | AF516696 | CACNA2D3 | 4.68E − 11 | 33.67 | ||
Calcium channel, voltage-dependent, alpha 2/delta subunit 4 | NM_172364 | CACNA2D4 | 2.95E − 01 | −1.41 | ||
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 3 | NM_199248 | CACNB1 | 4.31E − 01 | −1.14 | ||
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 1 | NM_000723 | CACNB1 | 8.02E − 01 | −1.02 | ||
Calcium channel, voltage-dependent, beta 1 subunit, transcript variant 1 | NM_000723 | CACNB1 | 6.22E − 01 | 1.04 | ||
cDNA FLJ45229 fis, clone BRCAN2020972, | AK128769 | CACNB2 | 9.78E − 01 | 1.02 | ||
Calcium channel, voltage-dependent, beta 2 subunit, transcript variant 1 | NM_000724 | CACNB2 | 4.71E − 02 | 3.45 | ||
Calcium channel, voltage-dependent, beta 3 subunit, transcript variant 1 | NM_000725 | CACNB3 | 3.55E − 02 | −1.93 | 9.56 | |
Calcium channel, voltage-dependent, beta 3 subunit, transcript variant 1 | NM_000725 | CACNB3 | 6.61E − 01 | 1.09 | ||
Calcium channel, voltage-dependent, beta 4 subunit, transcript variant 1 | NM_001005747 | CACNB4 | 1.33E − 03 | 4.43 | ||
Calcium channel, voltage-dependent, gamma subunit 1 | NM_000727 | CACNG1 | 9.46E − 01 | 1.02 | ||
Calcium channel, voltage-dependent, gamma subunit 2 | NM_006078 | CACNG2 | 4.19E − 01 | −1.29 | ||
Calcium channel, voltage-dependent, gamma subunit 2 | NM_006078 | CACNG2 | 7.91E − 01 | 1.09 | ||
Calcium channel, voltage-dependent, gamma subunit 3 | NM_006539 | CACNG3 | 2.21E − 01 | −1.95 | ||
Calcium channel, voltage-dependent, gamma subunit 4 | NM_014405 | CACNG4 | 4.93E − 01 | 1.14 | ||
Calcium channel, voltage-dependent, gamma subunit 5 | NM_145811 | CACNG5 | 7.49E − 01 | −1.13 | ||
Calcium channel, voltage-dependent, gamma subunit 5 [Source: HGNC Symbol; Acc: 1409] | ENST00000169565 | CACNG5 | 2.19E − 01 | −1.56 | ||
Calcium channel, voltage-dependent, gamma subunit 6, transcript variant 1 | NM_145814 | CACNG6 | 5.56E − 11 | 46.40 | ||
Calcium channel, voltage-dependent, gamma subunit 7 | NM_031896 | CACNG7 | 3.54E − 13 | 1439.36 | 3.37 | |
Calcium channel, voltage-dependent, gamma subunit 7 | NM_031896 | CACNG7 | 1.82E − 01 | 1.26 | ||
Calcium channel, voltage-dependent, gamma subunit 8 | NM_031895 | CACNG8 | 2.01E − 01 | 1.43 | ||
Calcium channel, voltage-dependent, gamma subunit 8 | NM_031895 | CACNG8 | 1.18E − 09 | 9.70 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Cation channel, sperm associated 1 | NM_053054 | CATSPER1 | 3.26E − 01 | 1.51 | ||
Cation channel, sperm associated 2, transcript variant 2 | NM_172095 | CATSPER2 | 1.32 E−04 | −2.78 | ||
Cation channel, sperm associated 2, transcript variant 4 | NM_172097 | CATSPER2 | 3.12E − 02 | −1.78 | ||
Cation channel, sperm associated 3 | NM_178019 | CATSPER3 | 1.50E − 03 | 1.93 | ||
Cation channel, sperm associated 4 | NM_198137 | CATSPER4 | 2.51E − 01 | 1.48 | ||
Cation channel, sperm-associated, beta | NM_024764 | CATSPERB | 4.38E − 01 | −1.25 | ||
Cation channel, sperm-associated, gamma | NM_021185 | CATSPERG | 3.56E − 01 | 1.34 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Cholinergic receptor, nicotinic, alpha 1 (muscle), transcript variant 1 | NM_001039523 | CHRNA1 | 8.06E − 01 | −1.10 | ||
Cholinergic receptor, nicotinic, alpha 1 (muscle), (cDNA clone IMAGE: 4124038), with apparent retained intron | BC006314 | CHRNA1 | 4.64E − 01 | 1.47 | ||
Cholinergic receptor, nicotinic, alpha 2 (neuronal) | NM_000742 | CHRNA2 | 6.05E − 01 | −1.30 | ||
Cholinergic receptor, nicotinic, alpha 3, transcript variant 1 | NM_000743 | CHRNA3 | 1.84E − 10 | 34.22 | ||
Cholinergic receptor, nicotinic, alpha 4 | NM_000744 | CHRNA4 | 6.79E − 01 | 1.15 | ||
Cholinergic receptor, nicotinic, alpha 4 (neuronal), exon 1 | X89741 | CHRNA4 | 2.79 E−02 | −2.53 | ||
Cholinergic receptor, nicotinic, alpha 5 | NM_000745 | CHRNA5 | 4.03E − 05 | 3.41 | ||
Cholinergic receptor, nicotinic, alpha 6, transcript variant 1 | NM_004198 | CHRNA6 | 2.23E − 01 | −1.27 | 2.21 | |
Cholinergic receptor, nicotinic, alpha 7, transcript variant 1 | NM_000746 | CHRNA7 | 4.61E − 04 | 1.86 | ||
Cholinergic receptor, nicotinic, alpha 7, transcript variant 2 | NM_001190455 | CHRNA7 | 1.56E − 11 | 13.24 | ||
Cholinergic receptor, nicotinic, alpha 9 | NM_017581 | CHRNA9 | 6.30E − 06 | 6.15 | ||
Cholinergic receptor, nicotinic, alpha 10 | NM_020402 | CHRNA10 | 1.57E − 02 | 1.57 | ||
Cholinergic receptor, nicotinic, beta 1 (muscle) | NM_000747 | CHRNB1 | 8.07 E−04 | −2.47 | ||
Cholinergic receptor, nicotinic, beta 1 (muscle) | NM_000747 | CHRNB1 | 8.87E − 03 | −1.92 | ||
Cholinergic receptor, nicotinic, beta 2 (neuronal) | NM_000748 | CHRNB2 | 6.03 E−04 | −3.01 | ||
Cholinergic receptor, nicotinic, beta 2 (neuronal) [Source: HGNC Symbol; Acc: 1962] | ENST00000368476 | CHRNB2 | 2.98E − 09 | 32.05 | ||
Cholinergic receptor, nicotinic, beta 3 | NM_000749 | CHRNB3 | 5.91E − 01 | 1.12 | ||
Cholinergic receptor, nicotinic, beta 4 | NM_000750 | CHRNB4 | 1.76E − 02 | 4.20 | ||
Cholinergic receptor, nicotinic, delta | NM_000751 | CHRND | 9.84E − 01 | 1.01 | ||
Cholinergic receptor, nicotinic, epsilon | NM_000080 | CHRNE | 3.66E − 01 | −1.20 | ||
Cholinergic receptor, nicotinic, gamma | NM_005199 | CHRNG | 6.70E − 01 | 1.14 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Cyclic nucleotide-gated channel alpha 1, transcript variant 2 | NM_000087 | CNGA1 | 7.14E − 01 | 1.15 | ||
Cyclic nucleotide-gated channel alpha 1, transcript variant 2 | NM_000087 | CNGA1 | 1.18E − 02 | 2.00 | ||
Cyclic nucleotide-gated channel alpha 3, transcript variant 1 | NM_001298 | CNGA3 | 2.00E − 01 | 1.21 | ||
Cyclic nucleotide-gated channel alpha 4 | NM_001037329 | CNGA4 | 2.78E − 01 | 1.82 | ||
Cyclic nucleotide-gated channel beta 1, transcript variant 1 | NM_001297 | CNGB1 | 9.22 E−03 | −2.05 | ||
Cyclic nucleotide-gated channel beta 1, transcript variant 1 | NM_001297 | CNGB1 | 6.36E − 01 | −1.13 | ||
Cyclic nucleotide-gated channel beta 3 | NM_019098 | CNGB3 | 2.93E − 01 | 1.78 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Gamma-aminobutyric acid (GABA) A receptor, alpha 1, transcript variant 1 | NM_000806 | GABRA1 | 1.26E − 01 | 1.41 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 1, transcript variant 1 | NM_000806 | GABRA1 | 8.87E − 01 | 1.05 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 2, transcript variant 1 | NM_000807 | GABRA2 | 9.70E − 02 | 1.70 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 2, transcript variant 1 | NM_000807 | GABRA2 | 4.49E − 01 | 1.48 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 3 | NM_000808 | GABRA3 | 2.10E − 01 | 1.43 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 4, transcript variant 1 | NM_000809 | GABRA4 | 3.76E − 01 | 1.43 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 4, transcript variant 1 | NM_000809 | GABRA4 | 8.30E − 01 | 1.05 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 5, transcript variant 1 | NM_000810 | GABRA5 | 1.09E − 08 | 14.41 | ||
Gamma-aminobutyric acid (GABA) A receptor, alpha 6 | NM_000811 | GABRA6 | 1.69E − 01 | 1.23 | ||
Gamma-aminobutyric acid (GABA) A receptor, beta 1 | NM_000812 | GABRB1 | 1.14E − 01 | 1.43 | ||
Gamma-aminobutyric acid (GABA) A receptor, beta 2, transcript variant 2 | NM_000813 | GABRB2 | 1.27E − 02 | 1.94 | ||
Gamma-aminobutyric acid (GABA) A receptor, beta 3, transcript variant 1 | NM_000814 | GABRB3 | 6.70E − 10 | 85.93 | −4.49 | |
Gamma-aminobutyric acid (GABA) A receptor, beta 3, transcript variant 1 | NM_000814 | GABRB3 | 1.15E − 09 | 115.69 | ||
Gamma-aminobutyric acid (GABA) A receptor, delta | NM_000815 | GABRD | 6.26E − 02 | 3.02 | ||
Gamma-aminobutyric acid (GABA) A receptor, epsilon | NM_004961 | GABRE | 5.83 E−05 | −5.47 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 1 | NM_173536 | GABRG1 | 1.78E − 01 | 1.24 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 1 | NM_173536 | GABRG1 | 1.70E − 02 | 2.19 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 1 | NM_198904 | GABRG2 | 6.02E − 01 | 1.14 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 2 | NM_000816 | GABRG2 | 5.28E − 02 | 1.72 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 2, transcript variant 2 | NM_000816 | GABRG2 | 9.47E − 09 | 8.41 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 3 | NM_033223 | GABRG3 | 1.99E − 01 | 2.00 | ||
Gamma-aminobutyric acid (GABA) A receptor, Gamma 3 | NM_033223 | GABRG3 | 1.04E − 01 | 1.61 | ||
Gamma-aminobutyric acid (GABA) A receptor, pi | NM_014211 | GABRP | 6.62E − 01 | −1.12 | 17.25 | |
Gamma-aminobutyric acid (GABA) receptor, theta | NM_018558 | GABRQ | 1.60E − 01 | 1.56 | ||
Gamma-aminobutyric acid (GABA) receptor, theta | NM_018558 | GABRQ | 4.76E − 01 | −1.27 | ||
Gamma-aminobutyric acid (GABA) receptor, theta [Source: HGNC Symbol; Acc: 14454] | ENST00000370306 | GABRQ | 8.22E − 09 | 52.17 | ||
Gamma-aminobutyric acid (GABA) receptor, rho 1 | NM_002042 | GABRR1 | 8.94E − 01 | −1.04 | ||
Gamma-aminobutyric acid (GABA) receptor, rho 2 | NM_002043 | GABRR2 | 2.83E − 01 | 1.54 | ||
Gamma-aminobutyric acid (GABA) receptor, rho 3 | NM_001105580 | GABRR3 | 3.05E − 01 | −1.34 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Glycine receptor, alpha 1, transcript variant 2 | NM_000171 | GLRA1 | 5.47E − 01 | −1.29 | ||
Glycine receptor, alpha 2, transcript variant 1 | NM_002063 | GLRA2 | 1.17E − 01 | 1.42 | 11.41 | |
Glycine receptor, alpha 3, transcript variant 1 | NM_006529 | GLRA3 | 5.16E − 01 | −1.26 | ||
Glycine receptor, alpha 3 [Source: HGNC Symbol; Acc: 4328] | ENST00000274093 | GLRA3 | 8.33E − 02 | 1.64 | ||
Glycine receptor, alpha 3, transcript variant 1 | NM_006529 | GLRA3 | 1.46E − 01 | 1.41 | ||
Glycine receptor, alpha 4, transcript variant 1 | NM_001024452 | GLRA4 | 7.75E − 01 | 1.17 | ||
Glycine receptor, beta, transcript variant 1 | NM_000824 | GLRB | 6.38E − 02 | −1.69 | 6.61 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Glutamate receptor, ionotropic, AMPA 1, transcript variant 1 | NM_000827 | GRIA1 | 7.65E − 01 | −1.20 | 2.06 | |
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1 | NM_000826 | GRIA2 | 2.87E − 01 | −1.87 | 21.26 | |
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1 | NM_000826 | GRIA2 | 2.72E − 01 | 1.33 | ||
Glutamate receptor, ionotropic, AMPA 2, transcript variant 1 | NM_000826 | GRIA2 | 6.54E − 01 | 1.22 | ||
Glutamate receptor, ionotropic, AMPA 3, transcript variant 2 | NM_000828 | GRIA3 | 5.05E − 01 | 1.26 | ||
Glutamate receptor, ionotropic, AMPA 3 [Source: HGNC Symbol; Acc: 4573] | ENST00000371264 | GRIA3 | 1.14E − 01 | 1.50 | ||
Glutamate receptor, ionotropic, AMPA 3, transcript variant 2 | NM_000828 | GRIA3 | 9.05E − 01 | −1.05 | ||
Glutamate receptor, ionotropic, AMPA 4, transcript variant 1 | NM_000829 | GRIA4 | 2.30E − 02 | 1.80 | 3.73 | |
Glutamate receptor, ionotropic, delta 1 | NM_017551 | GRID1 | 1.82E − 01 | 1.50 | ||
Glutamate receptor, ionotropic, delta 1 | NM_017551 | GRID1 | 5.08E − 05 | 3.63 | ||
Glutamate receptor, ionotropic, delta 2 | NM_001510 | GRID2 | 7.64E − 01 | −1.11 | ||
Glutamate receptor, ionotropic, delta 2 | NM_001510 | GRID2 | 5.55E − 09 | 55.66 | ||
Glutamate receptor, ionotropic, kainate 1, transcript variant 1 | NM_000830 | GRIK1 | 1.64E − 01 | 1.29 | 2.58 | |
Glutamate receptor, ionotropic, kainate 2, transcript variant 3 | NM_001166247 | GRIK2 | 1.42E − 01 | 1.56 | 2.53 | |
Glutamate receptor, ionotropic, kainate 2, transcript variant 1 | NM_021956 | GRIK2 | 1.14E − 01 | −2.01 | ||
Glutamate receptor, ionotropic, kainate 2, transcript variant 2 | NM_175768 | GRIK2 | 7.80E − 01 | 1.08 | ||
Glutamate receptor, ionotropic, kainate 3 | NM_000831 | GRIK3 | 1.58E − 01 | 1.64 | ||
Glutamate receptor, ionotropic, kainate 3 | NM_000831 | GRIK3 | 6.15E − 10 | 22.64 | ||
Glutamate receptor, ionotropic, kainate 4 [Source: HGNC Symbol; Acc: 4582] | ENST00000527524 | GRIK4 | 1.77E − 11 | 18.10 | ||
Glutamate receptor, ionotropic, kainate 4 | NM_014619 | GRIK4 | 5.73E − 02 | 2.54 | ||
Glutamate receptor, ionotropic, kainate 5 | NM_002088 | GRIK5 | 2.65E − 03 | 1.79 | −2.41 | |
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3 | NM_007327 | GRIN1 | 1.93 E−02 | −3.02 | 2.69 | |
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3 | NM_007327 | GRIN1 | 6.01E − 02 | −2.45 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 1, transcript variant NR1-3 | NM_007327 | GRIN1 | 3.86E − 01 | −1.65 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2 | NM_000833 | GRIN2A | 6.54E − 01 | 1.18 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2 | NM_000833 | GRIN2A | 9.21E − 01 | −1.02 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 1 | NM_001134407 | GRIN2A | 3.32E − 10 | 29.85 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2A, transcript variant 2 | NM_000833 | GRIN2A | 2.63E − 01 | 1.55 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2B | NM_000834 | GRIN2B | 6.64E − 01 | −1.26 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | NM_000835 | GRIN2C | 8.01E − 01 | −1.08 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | NM_000835 | GRIN2C | 5.01E − 01 | 1.13 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate 2D | NM_000836 | GRIN2D | 4.69E − 02 | −1.82 | ||
Glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | NM_133445 | GRIN3A | 3.28E − 01 | −1.41 | ||
Glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | NM_138690 | GRIN3B | 9.36E − 01 | −1.02 | ||
Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding), transcript variant 1 | NM_000837 | GRINA | 3.68 E−04 | −2.05 | 2.05 | |
NMDA receptor glutamate-binding chain (hnrgw), partial | U44954 | GRINA | 3.06E − 04 | −1.81 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 | NM_021072 | HCN1 | 3.47E − 11 | 52.85 | ||
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 1 | NM_021072 | HCN1 | 1.01E − 08 | 9.91 | ||
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 2 | NM_001194 | HCN2 | 5.36E − 02 | −1.63 | ||
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 3 | NM_020897 | HCN3 | 1.98E − 02 | 2.12 | 6.56 | |
Hyperpolarization-activated cyclic nucleotide-gated potassium channel 4 | NM_005477 | HCN4 | 1.01E − 01 | −1.66 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
5-hydroxytryptamine (serotonin) receptor 3A, transcript variant 1 | NM_213621 | HTR3A | 1.99E − 03 | 2.77 | −2.20 | |
5-hydroxytryptamine (serotonin) receptor 3A, transcript variant 1 | NM_213621 | HTR3A | 2.63E − 11 | 11.11 | ||
5-hydroxytryptamine (serotonin) receptor 3B | NM_006028 | HTR3B | 1.99E − 01 | −1.54 | ||
5-hydroxytryptamine (serotonin) receptor 3, family member C | NM_130770 | HTR3C | 4.81E − 01 | 1.34 | ||
5-hydroxytryptamine (serotonin) receptor 3 family member D, transcript variant 2 | NM_182537 | HTR3D | 4.75E − 01 | −1.37 | ||
5-hydroxytryptamine (serotonin) receptor 3, family member E | NM_182589 | HTR3E | 1.52E − 01 | −1.44 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | NM_000217 | KCNA1 | 1.64E − 01 | 2.00 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | NM_000217 | KCNA1 | 1.31E − 01 | 1.87 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 2, transcript variant 2 | NM_001204269 | KCNA2 | 8.55E − 02 | 1.33 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 2, transcript variant 1 | NM_004974 | KCNA2 | 8.33E − 01 | 1.06 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 3 | NM_002232 | KCNA3 | 2.43E − 01 | 1.76 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 4 | NM_002233 | KCNA4 | 5.75E − 01 | 1.11 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 5 | NM_002234 | KCNA5 | 1.76E − 04 | 4.11 | 5.63 | |
Potassium voltage-gated channel, shaker-related subfamily, member 6 | NM_002235 | KCNA6 | 7.20E − 02 | 2.28 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 7 | NM_031886 | KCNA7 | 8.53E − 03 | 3.67 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 7 | NM_031886 | KCNA7 | 1.04E − 01 | 2.39 | ||
Potassium voltage-gated channel, shaker-related subfamily, member 10 | NM_005549 | KCNA10 | 3.32E − 01 | −1.62 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2 | NM_003471 | KCNAB1 | 2.70E − 01 | 1.46 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2 | NM_003471 | KCNAB1 | 3.60E − 02 | 2.42 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 1, transcript variant 2 | NM_003471 | KCNAB1 | 7.87E − 02 | 3.06 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 2, transcript variant 1 | NM_003636 | KCNAB2 | 5.35E − 01 | −1.35 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 2, transcript variant 1 | NM_003636 | KCNAB2 | 2.20E − 01 | 1.26 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 3 [Source: HGNC Symbol; Acc: 6230] | ENST00000303790 | KCNAB3 | 8.14E − 02 | 1.62 | ||
Potassium voltage-gated channel, shaker-related subfamily, beta member 3 | NM_004732 | KCNAB3 | 3.66E − 01 | 1.35 | ||
Potassium voltage-gated channel, Shab-related subfamily, member 1 | NM_004975 | KCNB1 | 7.42E − 08 | 16.32 | 2.59 | |
Potassium voltage-gated channel, Shab-related subfamily, member 2 | NM_004770 | KCNB2 | 1.54E − 05 | 4.58 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant A | NM_001112741 | KCNC1 | 1.47E − 01 | 1.75 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant B | NM_004976 | KCNC1 | 4.86E − 08 | 13.97 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 1, transcript variant A | NM_001112741 | KCNC1 | 2.17E − 01 | 1.56 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 2, transcript variant 1 | NM_139136 | KCNC2 | 8.53E − 01 | 1.06 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 2, transcript variant 2 | NM_139137 | KCNC2 | 4.04E − 01 | 1.34 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 3 | NM_004977 | KCNC3 | 3.56E − 01 | 1.20 | ||
Potassium voltage-gated channel, Shaw-related subfamily, member 4, transcript variant 3 | NM_001039574 | KCNC4 | 7.70E − 02 | −1.40 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 1 | NM_004979 | KCND1 | 1.48E − 04 | 7.11 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 2 | NM_012281 | KCND2 | 1.62E − 12 | 91.08 | 2.76 | −2.57 |
Potassium voltage-gated channel, Shal-related subfamily, member 2 | NM_012281 | KCND2 | 2.76E − 09 | 21.83 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 3 [Source: HGNC Symbol; Acc: 6239] | ENST00000369697 | KCND3 | 5.36E − 01 | −1.36 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 3, transcript variant 1 | NM_004980 | KCND3 | 1.05E − 01 | 1.55 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 3, transcript variant 1 | NM_004980 | KCND3 | 4.41E − 01 | 1.37 | ||
Potassium voltage-gated channel, Shal-related subfamily, member 3 [Source: HGNC Symbol; Acc: 6239] | ENST00000369697 | KCND3 | 3.86E − 04 | −1.84 | ||
Potassium voltage-gated channel, Isk-related family, member 1, transcript variant 2 | NM_000219 | KCNE1 | 3.53E − 01 | −1.45 | ||
Potassium voltage-gated channel, Isk-related family, member 1, transcript variant 2 | NM_000219 | KCNE1 | 3.59E − 01 | 1.25 | ||
KCNE1-like | NM_012282 | KCNE1L | 1.34E − 08 | 4.44 | −2.18 | |
KCNE1-like | NM_012282 | KCNE1L | 1.11E − 08 | 3.65 | ||
KCNE1-like | NM_012282 | KCNE1L | 6.41E − 03 | 1.88 | ||
Potassium voltage-gated channel, Isk-related family, member 2 | NM_172201 | KCNE2 | 1.41E − 04 | 3.93 | ||
Potassium voltage-gated channel, Isk-related family, member 3 | NM_005472 | KCNE3 | 8.65E − 15 | 52.36 | ||
Potassium voltage-gated channel, Isk-related family, member 4 | NM_080671 | KCNE4 | 5.04E − 01 | 1.20 | ||
Potassium voltage-gated channel, subfamily F, member 1 | NM_002236 | KCNF1 | 2.25E − 05 | 6.48 | 2.84 | |
Potassium voltage-gated channel, subfamily G, member 1 | NM_002237 | KCNG1 | 8.51E − 03 | −1.82 | ||
Potassium voltage-gated channel, subfamily G, member 1 | NM_002237 | KCNG1 | 1.55E − 01 | −1.65 | ||
Potassium voltage-gated channel, subfamily G, member 2 | NM_012283 | KCNG2 | 6.21E − 02 | 1.32 | ||
Potassium voltage-gated channel, subfamily G, member 3, transcript variant 1 | NM_133329 | KCNG3 | 3.74E − 11 | 58.95 | −2.93 | |
Potassium voltage-gated channel, subfamily G, member 4 | NM_172347 | KCNG4 | 3.36 E−03 | −3.33 | ||
Potassium voltage-gated channel, subfamily G, member 4, (cDNA clone IMAGE: 3028985) | BC008969 | KCNG4 | 2.24 E−04 | −3.29 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 1, transcript variant 1 | NM_172362 | KCNH1 | 8.05E − 01 | −1.15 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 2, transcript variant 1 | NM_000238 | KCNH2 | 5.94E − 04 | 37.53 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 2, transcript variant 2 | NM_172056 | KCNH2 | 5.70E − 03 | 1.73 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 3 | NM_012284 | KCNH3 | 9.65E − 01 | 1.01 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 4 | NM_012285 | KCNH4 | 3.18E − 01 | −1.24 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 5, transcript variant 2 | NM_172376 | KCNH5 | 3.04E − 03 | 2.96 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 5, transcript variant 1 | NM_139318 | KCNH5 | 5.41E − 01 | 1.47 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 6, transcript variant 2 | NM_173092 | KCNH6 | 2.93E − 02 | 3.04 | ||
cDNA FLJ33650 fis, clone BRAMY2024514, highly similar to Rattus norvegicus Potassium channel (erg2) | AK090969 | KCNH6 | 2.08E − 05 | 12.42 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 6, transcript variant 2 | NM_173092 | KCNH6 | 2.55E − 02 | 2.29 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 7, transcript variant 2 | NM_173162 | KCNH7 | 4.63E − 01 | −1.40 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 7, transcript variant 1 | NM_033272 | KCNH7 | 7.58E − 01 | −1.09 | ||
Potassium voltage-gated channel, subfamily H (eag-related), member 8 | NM_144633 | KCNH8 | 3.00E − 09 | 24.57 | 2.97 | |
Kv channel interacting protein 1, transcript variant 1 | NM_001034837 | KCNIP1 | 8.33E − 02 | 1.96 | 4.24 | |
Kv channel interacting protein 2, transcript variant 7 | NM_173197 | KCNIP2 | 6.43E − 01 | 1.21 | ||
Kv channel interacting protein 2, transcript variant 1 | NM_014591 | KCNIP2 | 2.53E − 03 | 1.96 | ||
Kv channel interacting protein 3, calsenilin, transcript variant 1 | NM_013434 | KCNIP3 | 1.15 E−03 | −3.47 | ||
Kv channel interacting protein 4, transcript variant 5 | NM_001035003 | KCNIP4 | 6.73E − 01 | 1.16 | 2.01 | |
Kv channel interacting protein 4, transcript variant 5 | NM_001035003 | KCNIP4 | 9.26E − 01 | 1.05 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 1, transcript variant 1 | NM_000218 | KCNQ1 | 3.31E − 09 | 79.52 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 2, transcript variant 5 | NM_172109 | KCNQ2 | 5.68E − 19 | 3408.43 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 2, transcript variant 3 | NM_004518 | KCNQ2 | 1.29E − 02 | 1.82 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 2, (cDNA clone IMAGE: 4154700) | BC020384 | KCNQ2 | 1.09E − 08 | 37.12 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 3, transcript variant 1 | NM_004519 | KCNQ3 | 1.10E − 04 | −1.69 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 4, transcript variant 1 | NM_004700 | KCNQ4 | 9.77E − 01 | 1.02 | ||
Potassium voltage-gated channel, KQT-like subfamily, member 5, transcript variant 1 | NM_019842 | KCNQ5 | 9.81E − 02 | −1.79 | ||
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1 | NM_002251 | KCNS1 | 3.39E − 01 | −1.27 | −2.64 | |
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 | NM_020697 | KCNS2 | 6.19E − 02 | −2.45 | 2.11 | |
Potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3 | NM_002252 | KCNS3 | 1.04E − 04 | 2.22 | −2.61 | −2.39 |
Potassium channel, subfamily T, member 1 (sodium activated) | NM_020822 | KCNT1 | 8.51E − 02 | −2.17 | ||
Potassium channel, subfamily V, member 1 | NM_014379 | KCNV1 | 7.84E − 02 | 1.58 | ||
Potassium channel, subfamily V, member 2 | NM_133497 | KCNV2 | 7.63E − 01 | −1.16 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Potassium inwardly-rectifying channel, subfamily J, member 1, transcript variant rom-k5 | NM_153767 | KCNJ1 | 2.54E − 02 | 2.66 | ||
Potassium inwardly-rectifying channel, subfamily J, member 1, transcript variant rom-k5 | NM_153767 | KCNJ1 | 8.51E − 01 | −1.05 | ||
Potassium inwardly-rectifying channel, subfamily J, member 2 | NM_000891 | KCNJ2 | 5.14E − 04 | 4.38 | ||
Potassium inwardly-rectifying channel, subfamily J, member 3 | NM_002239 | KCNJ3 | 4.56E − 01 | 1.34 | ||
Potassium inwardly-rectifying channel, subfamily J, member 4, transcript variant 1 | NM_152868 | KCNJ4 | 4.80E − 02 | 2.30 | ||
Potassium inwardly-rectifying channel, subfamily J, member 5 | NM_000890 | KCNJ5 | 1.88 E−08 | −45.40 | ||
Potassium inwardly-rectifying channel, subfamily J, member 5 | NM_000890 | KCNJ5 | 4.42 E−12 | −109.11 | ||
Potassium inwardly-rectifying channel, subfamily J, member 6 | NM_002240 | KCNJ6 | 3.29E − 05 | 6.75 | 5.54 | |
Potassium inwardly-rectifying channel, subfamily J, member 8 | NM_004982 | KCNJ8 | 1.98E − 04 | 5.97 | 2.74 | |
Potassium inwardly-rectifying channel, subfamily J, member 9 [Source: HGNC Symbol; Acc: 6270] | ENST00000368088 | KCNJ9 | 3.17E − 01 | 1.49 | ||
Potassium inwardly-rectifying channel, subfamily J, member 9 | NM_004983 | KCNJ9 | 3.07E − 01 | 1.79 | ||
Potassium inwardly-rectifying channel, subfamily J, member 10 | NM_002241 | KCNJ10 | 8.85E − 04 | 4.14 | ||
Potassium inwardly-rectifying channel, subfamily J, member 10 | NM_002241 | KCNJ10 | 9.56E − 01 | 1.01 | ||
Potassium inwardly-rectifying channel, subfamily J, member 11, transcript variant 1 | NM_000525 | KCNJ11 | 4.00E − 04 | 2.93 | ||
Potassium inwardly-rectifying channel, subfamily J, member 12 | NM_021012 | KCNJ12 | 1.00E − 01 | 1.47 | ||
Potassium inwardly-rectifying channel, subfamily J, member 12 | NM_021012 | KCNJ12 | 3.53E − 06 | 5.81 | ||
Potassium inwardly-rectifying channel, subfamily J, member 13, transcript variant 1 | NM_002242 | KCNJ13 | 7.75E − 01 | 1.20 | ||
Potassium inwardly-rectifying channel, subfamily J, member 14, transcript variant 2 | NM_170720 | KCNJ14 | 9.05E − 02 | −1.40 | ||
Potassium inwardly-rectifying channel, subfamily J, member 15, transcript variant 1 | NM_170736 | KCNJ15 | 3.41 E−08 | −150.95 | ||
Potassium inwardly-rectifying channel, subfamily J, member 16, transcript variant 2 | NM_170741 | KCNJ16 | 2.22E − 01 | −1.93 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Potassium channel, subfamily K, member 1 | NM_002245 | KCNK1 | 3.02E − 04 | −1.68 | ||
Potassium channel, subfamily K, member 2, transcript variant 1 | NM_001017424 | KCNK2 | 3.46E − 01 | 1.57 | ||
Potassium channel, subfamily K, member 3 | NM_002246 | KCNK3 | 9.98E − 01 | 1.00 | 2.36 | |
Potassium channel, subfamily K, member 3 | NM_002246 | KCNK3 | 8.75E − 01 | −1.10 | ||
Potassium channel, subfamily K, member 3 | NM_002246 | KCNK3 | 5.34E − 01 | −1.30 | ||
Potassium channel, subfamily K, member 3 [Source: HGNC Symbol; Acc: 6278] | ENST00000302909 | KCNK3 | 2.53E − 01 | 1.52 | ||
Potassium channel, subfamily K, member 4 | NM_033310 | KCNK4 | 6.21E − 01 | −1.14 | 2.05 | |
Potassium channel, subfamily K, member 5 | NM_003740 | KCNK5 | 1.16E − 14 | 29.46 | −2.35 | −2.03 |
Potassium channel, subfamily K, member 6 | NM_004823 | KCNK6 | 1.22 E−06 | −3.48 | −2.20 | |
Potassium channel, subfamily K, member 6 | NM_004823 | KCNK6 | 2.05 E−08 | −5.11 | ||
Potassium channel, subfamily K, member 6 | NM_004823 | KCNK6 | 7.04E−06 | −5.22 | ||
Potassium channel, subfamily K, member 7, transcript variant A | NM_033347 | KCNK7 | 1.17E − 01 | −1.52 | ||
Potassium channel, subfamily K, member 9 | NM_016601 | KCNK9 | 6.67E − 01 | −1.29 | ||
Potassium channel, subfamily K, member 10, transcript variant 1 | NM_021161 | KCNK10 | 2.63E − 01 | −1.30 | ||
Potassium channel, subfamily K, member 10, transcript variant 2 | NM_138317 | KCNK10 | 1.41E − 02 | 1.43 | ||
Potassium channel, subfamily K, member 12 | NM_022055 | KCNK12 | 4.58E − 10 | 23.40 | −5.58 | |
Potassium channel, subfamily K, member 13 | NM_022054 | KCNK13 | 7.65E − 01 | −1.10 | ||
Potassium channel, subfamily K, member 15 | NM_022358 | KCNK15 | 4.96E − 02 | −1.50 | ||
Potassium channel, subfamily K, member 15 | NM_022358 | KCNK15 | 9.10E − 01 | −1.09 | ||
Pancreatic potassium channel TALK-1d; alternatively spliced | AY253147 | KCNK16 | 2.17 E−02 | −2.43 | ||
Potassium channel, subfamily K, member 17, transcript variant 1 | NM_031460 | KCNK17 | 1.87E − 11 | 28.60 | ||
Potassium channel, subfamily K, member 17, transcript variant 1 | NM_031460 | KCNK17 | 1.52E − 05 | 19.62 | ||
Potassium channel, subfamily K, member 18 | NM_181840 | KCNK18 | 1.77E − 01 | 1.61 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2 | NM_002247 | KCNMA1 | 1.01E − 02 | 1.84 | 2.01 | |
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 1 | NM_001014797 | KCNMA1 | 3.19E − 01 | 1.32 | ||
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2 | NM_002247 | KCNMA1 | 3.67E − 03 | 2.27 | ||
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2 | NM_002247 | KCNMA1 | 8.53E − 02 | 1.44 | ||
Maxi-K channel HSLO | AF349445 | KCNMA1 | 3.04E − 01 | 1.44 | ||
Potassium large conductance calcium-activated channel, subfamily M, alpha member 1, transcript variant 2 | NM_002247 | KCNMA1 | 2.15E − 01 | −1.23 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 1 | NM_004137 | KCNMB1 | 7.12E − 02 | −1.41 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 1 | NM_004137 | KCNMB1 | 2.23E − 06 | 7.82 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 2, transcript variant 1 | NM_181361 | KCNMB2 | 3.36E − 01 | 1.56 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 2, transcript variant 1 | NM_181361 | KCNMB2 | 1.17E − 01 | 1.47 | ||
Potassium large conductance calcium-activated channel, subfamily M beta member 3, transcript variant 1 | NM_171828 | KCNMB3 | 1.41E − 05 | 2.63 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 4 | NM_014505 | KCNMB4 | 8.85E − 12 | 103.99 | ||
Potassium large conductance calcium-activated channel, subfamily M, beta member 4 [Source: HGNC Symbol; Acc: 6289] | ENST00000258111 | KCNMB4 | 9.22E − 10 | 18.40 | ||
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 | NM_002248 | KCNN1 | 3.40E − 05 | 4.67 | ||
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2, transcript variant 1 | NM_021614 | KCNN2 | 1.88E − 13 | 22.23 | −3.63 | |
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3, transcript variant 1 | NM_002249 | KCNN3 | 2.58E − 06 | 8.25 | ||
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3, transcript variant 3 | NM_001204087 | KCNN3 | 1.11E − 07 | 15.29 | ||
Potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | NM_002250 | KCNN4 | 1.06E − 02 | −1.84 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Purinergic receptor P2X, ligand-gated ion channel, 1 | NM_002558 | P2RX1 | 7.71E − 01 | 1.14 | ||
Purinergic receptor P2X, ligand-gated ion channel, 2, transcript variant 4 | NM_170683 | P2RX2 | 5.25E − 02 | −1.66 | ||
Purinergic receptor P2X, ligand-gated ion channel, 3 | NM_002559 | P2RX3 | 2.43E − 02 | −1.76 | ||
Purinergic receptor P2X, ligand-gated ion channel, 4 | NM_002560 | P2RX4 | 8.68E − 01 | −1.03 | ||
Purinergic receptor P2X, ligand-gated ion channel, 5, transcript variant 1 | NM_002561 | P2RX5 | 7.68E − 08 | 6.97 | ||
Purinergic receptor P2X, ligand-gated ion channel, 5, transcript variant 2 | NM_175080 | P2RX5 | 6.13E − 02 | 1.54 | ||
Purinergic receptor P2X, ligand-gated ion channel, 6 [Source: HGNC Symbol; Acc: 8538] | ENST00000413302 | P2RX6 | 4.13E − 01 | 1.68 | ||
Purinergic receptor P2X, ligand-gated ion channel, 7, transcript variant 1 | NM_002562 | P2RX7 | 6.13E − 01 | 1.23 | ||
Purinergic receptor P2X, ligand-gated ion channel, 7, transcript variant 1 | NM_002562 | P2RX7 | 9.17E − 01 | 1.04 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Polycystic kidney disease 2 (autosomal dominant) | NM_000297 | PKD2 | 7.48E − 07 | 1.79 | ||
Polycystic kidney disease 2 (autosomal dominant) | NM_000297 | PKD2 | 2.38E − 05 | 1.98 | ||
Polycystic kidney disease 2-like 1 | NM_016112 | PKD2L1 | 1.29E − 03 | 4.66 | ||
Polycystic kidney disease 2-like 2 | NM_014386 | PKD2L2 | 1.94E − 01 | 1.49 | ||
Polycystic kidney disease 2-like 2 | NM_014386 | PKD2L2 | 7.43E − 01 | 1.19 | ||
Polycystic kidney disease 2-like 2 | NM_014386 | PKD2L2 | 6.74E − 01 | 1.09 | ||
Transient receptor potential cation channel, subfamily A, member 1 | NM_007332 | TRPA1 | 2.99E − 01 | 1.74 | ||
Transient receptor potential cation channel, subfamily A, member 1 | NM_007332 | TRPA1 | 5.64E − 02 | 2.70 | ||
Transient receptor potential cation channel, subfamily C, member 1 | NM_003304 | TRPC1 | 4.30E − 06 | 2.01 | ||
Transient receptor potential cation channel, subfamily C, member 3, transcript variant 2 | NM_003305 | TRPC3 | 1.12E − 07 | 5.78 | 2.45 | |
Transient receptor potential cation channel, subfamily C, member 4, transcript variant alpha | NM_016179 | TRPC4 | 3.25E − 07 | 25.38 | ||
Transient receptor potential cation channel, subfamily C, member 5 | NM_012471 | TRPC5 | 1.20E − 01 | 1.28 | ||
Transient receptor potential cation channel, subfamily C, member 6 | NM_004621 | TRPC6 | 1.21E − 01 | 2.33 | ||
Transient receptor potential cation channel, subfamily C, member 7, transcript variant 1 | NM_020389 | TRPC7 | 6.18E − 01 | −1.36 | ||
Transient receptor potential cation channel, subfamily M, member 1 | NM_002420 | TRPM1 | 2.29E − 01 | 1.31 | ||
Transient receptor potential cation channel, subfamily M, member 2, transcript variant 1 | NM_003307 | TRPM2 | 1.22E − 01 | 1.97 | ||
Transient receptor potential cation channel, subfamily M, member 2, transcript variant 1 | NM_003307 | TRPM2 | 5.04E − 02 | 2.53 | ||
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 7 | NM_206948 | TRPM3 | 3.04E − 09 | 10.69 | ||
Transient receptor potential cation channel, subfamily M, member 3 [Source: HGNC Symbol; Acc: 17992] |
ENST00000354500 | TRPM3 | 2.34E − 03 | 3.74 | ||
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 7 | NM_206948 | TRPM3 | 3.41E − 06 | 6.23 | ||
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 9 | NM_001007471 | TRPM3 | 7.23E − 01 | 1.13 | ||
Transient receptor potential cation channel, subfamily M, member 3, transcript variant 9 | NM_001007471 | TRPM3 | 1.54E − 05 | 2.60 | ||
Transient receptor potential cation channel, subfamily M, member 4, transcript variant 1 | NM_017636 | TRPM4 | 3.72E − 02 | −1.89 | ||
Transient receptor potential cation channel, subfamily M, member 5 | NM_014555 | TRPM5 | 8.21E − 01 | −1.08 | ||
Transient receptor potential cation channel, subfamily M, member 6, transcript variant a | NM_017662 | TRPM6 | 3.80E − 01 | 1.64 | ||
Transient receptor potential cation channel, subfamily M, member 6, transcript variant a | NM_017662 | TRPM6 | 9.10E − 01 | 1.05 | ||
Transient receptor potential cation channel, subfamily M, member 6, transcript variant a | NM_017662 | TRPM6 | 5.32E − 07 | 5.59 | ||
Transient receptor potential cation channel, subfamily M, member 6, transcript variant a | NM_017662 | TRPM6 | 3.32E − 01 | 1.36 | ||
Transient receptor potential cation channel, subfamily M, member 7 | NM_017672 | TRPM7 | 2.16E − 02 | −1.25 | ||
Transient receptor potential cation channel, subfamily M, member 7 | NM_017672 | TRPM7 | 3.64E − 03 | −1.38 | ||
Transient receptor potential cation channel, subfamily M, member 8 | NM_024080 | TRPM8 | 2.04E − 01 | 1.89 | ||
Transient receptor potential cation channel, subfamily V, member 1, transcript variant 3 | NM_080706 | TRPV1 | 3.59E − 05 | 1.92 | ||
Transient receptor potential cation channel, subfamily V, member 1, transcript variant 3 | NM_080706 | TRPV1 | 4.14E − 05 | 2.25 | ||
Transient receptor potential cation channel, subfamily V, member 2 | NM_016113 | TRPV2 | 8.02E − 08 | 4.68 | ||
Transient receptor potential cation channel, subfamily V, member 3 | NM_145068 | TRPV3 | 4.64E − 01 | 1.35 | ||
Transient receptor potential cation channel, subfamily V, member 3 | NM_145068 | TRPV3 | 1.35E − 01 | −2.39 | ||
Transient receptor potential cation channel, subfamily V, member 4, transcript variant 2 | NM_147204 | TRPV4 | 4.33E − 01 | 1.39 | ||
Transient receptor potential cation channel, subfamily V, member 5, (cDNA clone MGC: 34269 IMAGE: 5186668) | BC034740 | TRPV5 | 1.00E − 01 | 1.38 | ||
Transient receptor potential cation channel, subfamily V, member 5 | NM_019841 | TRPV5 | 3.14E − 01 | −1.40 | ||
Transient receptor potential cation channel, subfamily V, member 6 | NM_018646 | TRPV6 | 1.57E − 01 | −1.38 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Sodium channel, voltage-gated, type I, alpha subunit, transcript variant 2 | NM_006920 | SCN1A | 1.98E − 01 | 1.54 | ||
Sodium channel, voltage-gated, type I, beta, transcript variant b | NM_199037 | SCN1B | 9.95E − 01 | −1.00 | ||
Sodium channel, voltage-gated, type II, alpha subunit, transcript variant 1 | NM_021007 | SCN2A | 4.16E − 01 | 1.62 | 5.00 | |
Sodium channel, voltage-gated, type II, beta | NM_004588 | SCN2B | 3.61E − 01 | −1.58 | ||
Sodium channel, voltage-gated, type II, beta | NM_004588 | SCN2B | 8.16 E−04 | −2.41 | ||
Sodium channel, voltage-gated, type III, alpha subunit, transcript variant 1 | NM_006922 | SCN3A | 2.87E − 01 | −2.00 | 2.85 | |
Sodium channel, voltage-gated, type III, alpha subunit, transcript variant 1 | NM_006922 | SCN3A | 1.89E − 01 | 1.49 | ||
Sodium channel, voltage-gated, type III, beta, transcript variant 1 | NM_018400 | SCN3B | 8.74E − 01 | −1.06 | 4.70 | |
Sodium channel, voltage-gated, type III, beta, transcript variant 1 | NM_018400 | SCN3B | 1.57E − 01 | −1.46 | ||
Sodium channel, voltage-gated, type III, beta, transcript variant 1 | NM_018400 | SCN3B | 1.56E − 01 | 1.96 | ||
Sodium channel, voltage-gated, type IV, alpha subunit | NM_000334 | SCN4A | 1.62E − 08 | 9.91 | ||
Sodium channel, voltage-gated, type IV, beta, transcript variant 1 | NM_174934 | SCN4B | 3.25 E−04 | −3.66 | ||
Sodium channel, voltage-gated, type V, alpha subunit, transcript variant 1 | NM_198056 | SCN5A | 2.43E − 08 | 14.10 | ||
Sodium channel, voltage-gated, type V, alpha subunit, transcript variant 2 | NM_000335 | SCN5A | 4.93E − 02 | 1.95 | ||
Sodium channel, voltage-gated, type VII, alpha | NM_002976 | SCN7A | 4.49E − 03 | 1.63 | ||
Sodium channel, voltage-gated, type VII, alpha | NM_002976 | SCN7A | 2.07E − 01 | 1.72 | ||
Sodium channel, voltage gated, type VIII, alpha subunit, transcript variant 1 | NM_014191 | SCN8A | 1.89E − 09 | 15.61 | ||
Sodium channel, voltage gated, type VIII, alpha subunit, transcript variant 1 | NM_014191 | SCN8A | 4.06E − 07 | 11.23 | ||
Sodium channel, voltage-gated, type IX, alpha subunit | NM_002977 | SCN9A | 4.08E − 08 | 11.51 | ||
Sodium channel, voltage-gated, type IX, alpha subunit | NM_002977 | SCN9A | 1.62E − 01 | 1.66 | ||
Sodium channel, voltage-gated, type IX, alpha subunit | NM_002977 | SCN9A | 3.38E − 03 | 2.57 | ||
Sodium channel, voltage-gated, type X, alpha subunit | NM_006514 | SCN10A | 4.06E − 01 | 1.35 | ||
Sodium channel, voltage-gated, type XI, alpha subunit | NM_014139 | SCN11A | 3.02E − 01 | 1.57 | ||
Sodium channel, voltage-gated, type XI, alpha subunit [Source: HGNC Symbol; Acc: 10583] | ENST00000444237 | SCN11A | 8.83E − 03 | 1.94 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Sodium channel, nonvoltage-gated 1 alpha, transcript variant 1 | NM_001038 | SCNN1A | 1.33E − 09 | 51.49 | −21.13 | −10.71 |
Sodium channel, nonvoltage-gated 1, beta | NM_000336 | SCNN1B | 2.11E − 01 | 1.64 | ||
Sodium channel, nonvoltage-gated 1, beta | NM_000336 | SCNN1B | 5.52E − 01 | 1.09 | ||
Sodium channel, nonvoltage-gated 1, delta, transcript variant 1 | NM_001130413 | SCNN1D | 8.43E − 02 | 1.49 | ||
Sodium channel, nonvoltage-gated 1, gamma | NM_001039 | SCNN1G | 2.33E − 01 | 1.59 | ||
Gamma subunit of epithelial amiloride-sensitive sodium channel | X87160 | SCNN1G | 3.99E − 01 | 1.27 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Two-pore segment channel 1, transcript variant 1 | NM_001143819 | TPCN1 | 6.20E − 04 | −1.76 | ||
Two-pore segment channel 1, transcript variant 2 | NM_017901 | TPCN1 | 1.71 E−03 | −2.10 | ||
Two-pore segment channel 1, transcript variant 2 | NM_017901 | TPCN1 | 3.55 E−04 | −2.44 | ||
Two-pore segment channel 1, transcript variant 1 | NM_001143819 | TPCN1 | 8.06E − 03 | −1.83 | ||
Two-pore segment channel 2 | NM_139075 | TPCN2 | 5.06E − 01 | −1.15 |
Gene name | Accession number | Gene symbol | P | Fold change Ker → hiPSC |
Fold change hiPSC → Neuron |
Fold change hiPSC → CM |
---|---|---|---|---|---|---|
Zinc-activated ligand-gated ion channel | NM_180990 | ZACN | 9.24E − 02 | 1.45 |
3.2. Voltage-Gated Calcium Channels
Voltage-gated calcium channels are crucially involved in the Ca2+-influx thereby playing an important role in calcium signaling of virtually all cells. High-voltage-gated calcium channels include the neural N-type channel, the poorly defined brain-specific R-type channel, the closely related P/Q-type channel, and the dihydropyridine-sensitive L-type channels responsible for excitation-contraction coupling of skeletal, smooth, and cardiac muscles as well as for hormone secretion in endocrine cells (reviewed in [24]). While mainly permeable for calcium ions they also show a low permeability for sodium ions. Upon depolarization of the cell they mediate a calcium influx into the cell. The channels consist of the main alpha subunit as well as regulatory beta, alpha 2/delta, and gamma subunits. The α 1 subunit forms the ion conducting pore while the associated subunits have several functions including modulation of gating [25]. CACNA1A mutations are for example involved in ataxia [26]. We have analyzed their expression with 42 probes. During reprogramming 14 (33%) of them are significantly upregulated while only 1 (2%) is significantly downregulated. From iPSCs to neurons, as expected, neuronal alpha-subunits CACNA1D, CACNA1E areupregulated together with several neuronal channel subunits (α 2 δ, β, and γ). In cardiomyocytes, solely the alpha subunit of the cardiac CACNA1C is upregulated. Of note, none of the differentiated progeny downregulated any voltage-gated calcium channels.
3.3. Sperm-Associated Cation Channels
Sperm-associated cation channels or CatSper channels are calcium ion channels. They are flagellar proteins involved in sperm motility and therefore affect fertility [27]. During reprogramming to iPSCs, from seven used probes just one showed a significant downregulation and none had a significant upregulation. We observed nothing noteworthy in the differentiated progeny.
3.4. Nicotinic Acetylcholine Receptors
Nicotinic acetylcholine receptors play a role in interneuronal synapses and neuromuscular junctions. They are composed of five subunits as homomeric or heteromeric receptors. They are located at the postsynaptic site and upon binding of acetylcholine they allow the transmission of cations, especially sodium and potassium ions, in some versions also calcium ions. This leads to a depolarization of the membrane and triggers further signaling pathways [28]. Several acetylcholine receptors and subunits are thought to play roles in a variety of pathomechanisms, for example, psychiatric disorders, cardiovascular diseases, or cancer [29–31]. From 21 probes, 5 (24%) showed a significant upregulation while 3 (14%) showed a significant downregulation from keratinocytes to iPSCs. In neurons, solely the neuronal nicotinic acetylcholine receptor CHRNA6 alpha subunit was upregulated, none in cardiomyocytes.
3.5. Cyclic Nucleotide-Gated Channels
Cyclic nucleotide-gated channels form tetrameric channels which—upon binding of cGMP—allow a flow of cations. For that, these channels track the intracellular concentration of cNMPs to produce a voltage response [32]. Their major role is the depolarization of rod photoreceptors, but they are also found in other tissues like olfactory sensory neurons [33], testis, kidney, or heart [34] and play a role in cellular development such as neuronal growth cone guidance [35]. Defects in these genes are reported to cause retinitis pigmentosa [36]. From 7 used probes one showed a significant upregulation and one showed a significant downregulation (both 14%) during reprogramming, while none was differentially regulated in differentiated neurons or cardiomyocytes.
3.6. GABA Receptors
GABA (gamma-aminobutyric acid) receptors are ligand-gated chloride channels. Since GABA is the main inhibitory neurotransmitter in the central nervous system GABA receptors play an important role for the brain function. The receptors are composed of five subunits which form heteromers. The GABA receptors are a drug target for anesthetics and other psychoactive drugs. We have analyzed 29 probes within GABA receptor subunits. From keratinocytes to iPSCs, 6 (21%) of them are significantly upregulated while just one (3%) is significantly downregulated. Interestingly, none was up- or downregulated in differentiated neurons, while GABRB3 was downregulated and GABRP was upregulated in cardiomyocytes. Up to now, more or less nothing is known about GABA receptors or their subunits in cardiac cells.
3.7. Glycine Receptors
Glycine receptors are inhibitory receptors of the postsynaptic site. They are activated by glycine and mediate an influx of chloride ions. Accordingly, GlyRs regulate not only the excitability of motor and sensory neurons but are also essential for the processing of photoreceptor signals, neuronal development, and inflammatory pain sensitization [37]. The heteromeric pore is formed by five subunits. Concerning their role in pathomechanisms, it was reported that mutations are causing hyperekplexia (also known as startle disease) [38]. We have analyzed 7 probes and none of them was significantly altered in hiPSCs. Transcript levels for the alpha2 subunit and the beta subunit were highly upregulated in differentiated neurons, pointing to their functional role in the nervous system.
3.8. Ionotropic Glutamate Receptors
Glutamate is the predominant excitatory neurotransmitter in the central nervous system. Therefore, ionotropic glutamate receptors play a key role for learning and memory processes. They are located in the postsynaptic membrane and are composed of several heteromeric subunits. Ionotropic glutamate receptors are further divided into AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate), NMDA (N-Methyl-D-aspartate) or kainate receptors depending on their sensitivity for the agonists. From 36 probes, 5 (14%) showed a significantly increased expression and 2 (6%) showed a decreased expression in iPSCs compared to keratinocytes. As expected, several subunits were upregulated in neurons (none downregulated). None was upregulated in cardiomyocytes, while the kainate subtype GRIK5 was downregulated.
3.9. Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels
Hyperpolarization-activated cyclic nucleotide-gated channels are homodimers or heterodimers and form a hyperpolarization-activated potassium channel. CNG channels display a very complex heteromeric structure with various subunits and domains that play a critical role in their function [39]. They contribute to pacemaker currents in the heart [40] but are also found in neurons [41]. We have analyzed 5 probes and 3 (60%) of them showed a significant upregulation while none was downregulated after reprogramming. In neurons the HCN3 channel transcript was upregulated, which plays a role in several neuronal functions including excitability of basal ganglia output neurons [42]. Although HCN4 for example plays a critical role in the conduction system of the heart, we did not observe a specific regulation in cardiomyocytes.
3.10. Serotonin Receptors
Serotonin (or 5-hydroxytryptamine) receptors are ligand-gated receptors mainly found presynaptically in neurons. The type 3 receptor is the only ion channel while the other serotonin receptors are G-protein-coupled receptors. It forms a heteropentameric pore which upon activation by serotonin allows the flow of sodium and potassium, leading to a depolarization. Serotonin receptors modulate neuronal function and are therefore involved in various brain functions. The analysis of 6 probes for type 3 serotonin receptors showed a significant upregulation of 2 (33%, both for HTR3A) probes while none was downregulated in hiPSCs. Although we expected serotonin receptors to be upregulated during neuronal differentiation, no subunit was upregulated in neurons or cardiomyocytes, while only the receptor transcript for HTR3A was downregulated in neurons.
3.11. Voltage-Gated Potassium Channels
Voltage-gated potassium channels are composed of a large group of subunits with different characteristics concerning for example their inactivation speed. Functional channels are formed by heterotetramers. The channels are highly specific for potassium with a low affinity for sodium or other cations. Voltage-gated potassium channels are responsible for the repolarization of excitable cells following the sodium-mediated excitation of an action potential and are therefore found in neurons and other cells displaying action potentials. We have analyzed 81 probes. From keratinocytes to hiPSCs, 25 (31%) were significantly upregulated while only 3 (4%) were significantly downregulated. In neurons, several subunits were upregulated including KCNB1, coding for Kv2.1 and KCND2, both are better known for their role in cardiac cell excitability as well as KCNF1, KCNH8, and KCNIP1, all known for their contribution in neuronal excitability [43]. It should be noted that KCNT1 is actually sodium activated but is included in the alphabetical list for a better overview. Further, several “S” subunits were upregulated (KCNS2 in neurons) or downregulated (KCNS3 in neurons; KCNS1 and 3 in cardiomyocytes). These subunits are unable to form functional channels as homotetramers but instead heterotetramerize with other alpha-subunits to form conductive channels. These subunits are involved in modifying the channels response and conductivity [44]. Few is known about distinct roles in other tissues, but they were associated with for example, pain modulation [45] or airway responsiveness [46].
3.12. Inwardly Rectifying Potassium Channels
Inwardly rectifying potassium channels have a higher tendency to allow the flow of potassium ions into the cell rather than to the outside of the cell. Therefore, they play an important role in the maintenance of the resting membrane potential. Their activation is constitutive or controlled by ATP binding and G-proteins [47]. Functional channels are formed as homo- or heterotetramers. These channels can be found predominantly in neurons, cardiac myocytes, the pancreas, or the kidneys. From 20 analyzed probes in hiPSCs compared to keratinocytes, 8 (40%) showed a significant upregulation and 3 (15%) were significantly downregulated. The GIRK2 channel encoded by KCNJ6 is upregulated in neurons playing multiple roles in various tissues including the pancreas and brain [48, 49] and is associated with epileptic seizures in mice lacking the gene [50]. On the other hand, Kir6.1, encoded by KCNJ8, is upregulated in cardiomyocytes and has been reported to be involved in the pathogenesis of cardiac arrest in the early repolarization syndrome [51].
3.13. Two-P Potassium Channels
Two-P potassium channels contain two pore-forming P domains. After dimerization they form an outward rectifying potassium channel. They can be found in several tissues and are activated by various chemical or physical means (TRAAK channels). We have analyzed 23 probes. 4 (17%) of them were significantly upregulated while 4 (17%) were significantly downregulated. In neurons KCNK3, vital for setting the resting membrane potential and primary target for volatile anesthetics [52] as well as KCNK4, which is mechanically gated and contributes to axonal pathfinding, growth cone motility, and neurite elongation, as well as possibly having a role in touch or pain detection [53, 54], were upregulated. KCNK5 and 6 were downregulated. In cardiomyocytes, downregulation of KCNK5 and 12 was observed.
3.14. Calcium-Activated Potassium Channels
Calcium-activated potassium channels are mostly activated by intracellular calcium; some family members are also voltage gated. The family consists of large, intermediate, and small conductance family members. Channels are formed by two units (KCNM family) or most commonly four units (KCNN family). They are involved in, for example, afterhyperpolarization following the action potential and are predominantly found in neurons. Additionally, they are known to play different roles in cellular mechanisms, including stem cell biology [4–6, 55]. We have analyzed 18 probes of which 9 (50%) were significantly upregulated and none was significantly downregulated after reprogramming. In neurons, solely KCNN2 was downregulated, while in cardiomyocytes KCNMA1, encoding the large conductance BK-channel, involved in heart rate regulation [56], was upregulated.
3.15. P2X Receptors
P2X receptors are receptors for extracellular ATP and upon activation open a channel for ions, predominantly calcium. The channel is formed by homo- or heterotrimers. They are found in several tissues, mainly in the nervous system and muscle tissue. They are involved in a range of physiological processes such as modulation of synaptic transmission, vascular tone, cardiac rhythm, and contractility and immune response [57–61]. In stem cells an influence of P2X receptors on embryonic stem cell proliferation was reported [62]. From the 9 analyzed probes 1 (11%) was significantly upregulated and none downregulated. None of these receptors/channels was regulated in differentiated progeny.
3.16. Transient Receptor Potential Channels
Transient receptor potential channels (TRP channels) are nonselective cation channels. They show different preferences for cations, as well as different activation mechanisms and functions. TRP channels are broadly expressed throughout the organism and mediate multiple functions. These include amongst others sensor activity for a wide range of hypertrophic stimuli and mutations in TRPM4 are now recognized as causes of human cardiac conduction disorders (reviewed in [63]). Furthermore, TRP channels are related to the onset or progression of several diseases, and defects in the genes encoding TRP channels (so-called “TRP channelopathies”) underlie certain neurodegenerative disorders due to their abnormal Ca2+ signaling properties (reviewed in [64]). Additionally, TRP channels influence stem cell differentiation and survival [65, 66] and are involved in neuronal-stem-cell-derived development [67]. We have analyzed 40 probes. After reprogramming, 11 (28%) of them were significantly upregulated and none was significantly downregulated. In neurons, none of these channels was noteworthily regulated while solely TRPC3 was upregulated in cardiomyocytes, reported to be involved in conduction disturbances induced by adenosine receptor A1AR by enhanced Ca2+ entry through the TRPC3 channel [68].
3.17. Voltage-Gated Sodium Channels
Voltage-gated sodium channels consist of a main alpha unit and some optional modulating or regulatory subunits. They are highly selective for sodium and are involved in a variety of cellular functions including action potential formation [69]. From 24 probes we have analyzed, 6 (25%) were significantly upregulated and two (8%) were significantly downregulated from keratinocytes to iPS cells. These channels seem to be expressed in different kinds of stem cells and during development [70–72]. It was further reported that, for example, SCN5A, highly upregulated in iPS cells, is involved in cancer stem cell invasion [73]. SCN2A, SCN3A, and SCN3B were upregulated in neurons, described to be involved in neuronal excitation and epilepsy pathogenesis [74]. Although voltage-gated sodium channels play multiple roles also in the cardiac system [70, 75, 76], we observed no changes of this channel family in cardiomyocytes.
3.18. Nonvoltage-Gated Sodium Channels
Epithelial nonvoltage-gated sodium channels are amiloride sensitive. They form heterotrimers and are involved in ion and fluid transport across epithelia in several organs. We have analyzed 6 probes and one (17%) of them was significantly upregulated while none was significantly downregulated. Interestingly, the upregulated SCNN1A in iPS cells was subsequently downregulated both in neurons and cardiomyocytes, pointing to a possible function in stem cells. Of note, it was shown already that repression of pluripotency by retinoic acid represses the SCNN1A gene together with several other pluripotency factors [77].
3.19. Two-Pore Channels
Two-pore channels are cation-selective ion channels activated by the second messenger nicotinic acid adenine dinucleotide phosphate (NAADP). Upon activation calcium is released from intracellular stores [78]. We have analyzed 5 probes and while none of them was significantly upregulated two (40%) were significantly downregulated from keratinocytes to iPS cells. None of these channels was regulated in neurons or cardiomyocytes.
3.20. Zinc-Activated Ligand-Gated Ion Channels
The zinc-activated ligand-gated ion channel is activated upon binding of zinc. Until now just one family member is known that is expressed in several tissues [79]. Its exact function is not known. The expression was not significantly altered as shown by one probe in all cells.
4. Discussion
Although ion channels are mainly known for their role in electrically excitable cells they can be found in almost all tissues and are additionally involved in various processes such as cell differentiation and maturation [3, 4, 6, 12, 24, 47, 70]. These large groups of channel proteins are still underestimated concerning their role during embryonic development and cell fate determination. One of the most interesting in vitro models for the elucidation of both developmental processes and disease-specific cellular impairments is represented by pluripotent stem cells. Therefore we were interested in the set of ion channels expressed in hiPSCs after reprogramming and compared this set with iPSC-derived differentiated progeny, namely, neurons and cardiomyocytes. As little is known about ion channels in hiPSCs we aimed to start the analysis with gene expression microarray data. For a comparison, we chose the cells from which they were produced—namely, keratinocytes—as the reference cell type. The comparison of 6 keratinocyte samples with 9 hiPSC samples should minimize the often observed variances between hiPSC lines. We found out that almost a third (32%) of the ion channel probes we investigated showed a significant change in gene expression. Of note, this was mostly an upregulation. Additionally, while many ion channel genes were not expressed in keratinocytes they were present in hiPSCs. This indicates that several of the analyzed channel groups might play unknown roles in stem cell biology, for example, homeostasis, proliferation, or differentiation. Interestingly, after differentiation into neurons or cardiomyocytes, relatively small groups were subsequently regulated. This includes ion channel transcripts playing important roles in the respective tissues. Nevertheless, we compared already published sets of data from different experimental setups and additionally limited the analysis to a strong fold regulation. This might lead to high dropout rates of regulated genes during measurement. Still, various channel transcripts were “logically” up- or downregulated during differentiation into neurons or cardiomyocytes, following embryonic development. iPS cells and especially patient-specific iPS cells from persons suffering from genetic mutations leading to hereditary syndromes are a very valuable tool to investigate pathogenetic mechanisms and disease associated molecular and cellular changes [80–82]. As various channel subtypes are involved in multiple pathogenetic mechanisms it would be further interesting to analyze channel transcript regulation in patient specific iPS cells and their differentiated progeny to elucidate possible disease-specific pathways.
Concerning the presented study it is clear that gene regulations on transcript level do not explicitly mimic either protein levels and posttranslational modifications or protein activity. This set of data is sought to describe a global overview on transcript regulation of ion channels during distinct steps of development. It should be noted that in cases where several probes bind within one gene they do not indicate the same upregulation. Sometimes they show the same trend but miss significance, but for some cases there are considerable differences. This could hint for some yet unknown splicing variants. More detailed studies of these hypothesized splice variants could give insights into their function and broaden the still scarce knowledge.
This work is intended to be a guide and start point for future work focusing on single channels and their composition, localization, and function in hiPSCs and their differentiated progeny. These studies could lead to better in vitro differentiation protocols but also explain some of the many disease pathomechanisms related to mutations in ion channel genes.
Conflict of Interests
There is no conflict of interests to declare.
Acknowledgments
The authors thank Sabine Seltenheim for excellent technical assistance enabling research conducted in our laboratories. The research that enabled this paper was funded by a fellowship from the Medical Faculty of Ulm University (Bausteinprogramm, L. SBR.0011) and by the Deutsche Forschungsgemeinschaft (Alexander Kleger KL2544/1-1, Stefan Liebau BO1718/4-1), the German Foundation for Heart Research (F/34/11; to Alexander Kleger and Stefan Liebau), the Else-Kröner-Fresenius-Stiftung (2011_A200; to Alexander Kleger and Stefan Liebau), Boehringer-Ingelheim BIU (N5 to Stefan Liebau; C1 to Alexander Kleger), and the Helmholtz Gesellschaft (VH-VI-510 to Tobias M. Boeckers and Stefan Liebau). Alexander Kleger is indebted to the Baden-Württemberg Stiftung for the financial support of this research project by the Eliteprogramm for Postdocs.
References
- 1.Malissen B. A voltage-gated sodium channel mediates positive selection of T cells. Nature Immunology. 2012;13:810–812. doi: 10.1038/ni.2400. [DOI] [PubMed] [Google Scholar]
- 2.Rorsman P, Braun M. Regulation of insulin secretion in human pancreatic islets. Annual Review of Physiology. 2012;75:155–179. doi: 10.1146/annurev-physiol-030212-183754. [DOI] [PubMed] [Google Scholar]
- 3.Grant AO. Cardiac ion channels. Circulation. 2009;2(2):185–194. doi: 10.1161/CIRCEP.108.789081. [DOI] [PubMed] [Google Scholar]
- 4.Liebau S, Steinestel J, Linta L, et al. An SK3 channel/nWASP/Abi-1 complex is involved in early neurogenesis. PLoS ONE. 2011;6(3) doi: 10.1371/journal.pone.0018148.e18148 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Liebau S, Vaida B, Proepper C, et al. Formation of cellular projections in neural progenitor cells depends on SK3 channel activity. Journal of Neurochemistry. 2007;101(5):1338–1350. doi: 10.1111/j.1471-4159.2006.04437.x. [DOI] [PubMed] [Google Scholar]
- 6.Kleger A, Seufferlein T, Malan D, et al. Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation. 2010;122(18):1823–1836. doi: 10.1161/CIRCULATIONAHA.110.971721. [DOI] [PubMed] [Google Scholar]
- 7.Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–872. doi: 10.1016/j.cell.2007.11.019. [DOI] [PubMed] [Google Scholar]
- 8.Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676. doi: 10.1016/j.cell.2006.07.024. [DOI] [PubMed] [Google Scholar]
- 9.Carvajal-Vergara X, Sevilla A, Dsouza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465(7299):808–812. doi: 10.1038/nature09005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Stockmann M, Linta L, Fohr KJ, et al. Developmental and functional nature of human iPSC derived motoneurons. Stem Cell Reviews and Reports. 2011 doi: 10.1007/s12015-011-9329-4. [DOI] [PubMed] [Google Scholar]
- 11.Harrell MD, Harbi S, Hoffman JF, Zavadil J, Coetzee WA. Large-scale analysis of ion channel gene expression in the mouse heart during perinatal development. Physiological Genomics. 2007;28(3):273–283. doi: 10.1152/physiolgenomics.00163.2006. [DOI] [PubMed] [Google Scholar]
- 12.Davies MP, An RH, Doevendans P, Kubalak S, Chien KR, Kass RS. Developmental changes in ionic channel activity in the embryonic murine heart. Circulation Research. 1996;78(1):15–25. doi: 10.1161/01.res.78.1.15. [DOI] [PubMed] [Google Scholar]
- 13.Jäger H, Dreker T, Buck A, Giehl K, Gress T, Grissmer S. Blockage of intermediate-conductance Ca2+-Activated K+ channels inhibit human pancreatic cancer cell growth in vitro. Molecular Pharmacology. 2004;65(3):630–638. doi: 10.1124/mol.65.3.630. [DOI] [PubMed] [Google Scholar]
- 14.Müller M, Stockmann M, Malan D, et al. Ca2+ activated K channels-new tools to induce cardiac commitment from pluripotent stem cells in mice and men. Stem Cell Reviews and Reports. 2012;8(3):720–740. doi: 10.1007/s12015-011-9324-9. [DOI] [PubMed] [Google Scholar]
- 15.Wang SP, Wang JA, Luo RH, Cui WY, Wang H. Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation. Clinical and Experimental Pharmacology and Physiology. 2008;35(9):1077–1084. doi: 10.1111/j.1440-1681.2008.04964.x. [DOI] [PubMed] [Google Scholar]
- 16.Brennand KJ, Simone A, Jou J, et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature. 2011;473:221–225. doi: 10.1038/nature09915. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Liu GH, Barkho BZ, Ruiz S, et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature. 2011;472(7342):221–225. doi: 10.1038/nature09879. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Maehr R, Chen S, Snitow M, et al. Generation of pluripotent stem cells from patients with type 1 diabetes. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(37):15768–15773. doi: 10.1073/pnas.0906894106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hofman N, Wilde AAM, Kääb S, et al. Diagnostic criteria for congenital long QT syndrome in the era of molecular genetics: do we need a scoring system? European Heart Journal. 2007;28(5):575–580. doi: 10.1093/eurheartj/ehl355. [DOI] [PubMed] [Google Scholar]
- 20.Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell. 1995;80(5):795–803. doi: 10.1016/0092-8674(95)90358-5. [DOI] [PubMed] [Google Scholar]
- 21.Aasen T, Raya A, Barrero MJ, et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nature Biotechnology. 2008;26(11):1276–1284. doi: 10.1038/nbt.1503. [DOI] [PubMed] [Google Scholar]
- 22.Aasen T, Belmonte JCI. Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. Nature Protocols. 2010;5(2):371–382. doi: 10.1038/nprot.2009.241. [DOI] [PubMed] [Google Scholar]
- 23.Linta L, Stockmann M, Kleinhans KN, et al. Rat embryonic fibroblasts improve reprogramming of human keratinocytes into induced pluripotent stem cells. Stem Cells and Development. 2011;21(6):965–976. doi: 10.1089/scd.2011.0026. [DOI] [PubMed] [Google Scholar]
- 24.Catterall WA. Voltage-gated calcium channels. Cold Spring Harbor Perspectives in Biology. 2011;3(8) doi: 10.1101/cshperspect.a003947.a003947 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Dolphin AC. A short history of voltage-gated calcium channels. British Journal of Pharmacology. 2006;147(supplement 1):S56–S62. doi: 10.1038/sj.bjp.0706442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Magis D, Boon E, Coppola G, Daron A, Schoenen J. A novel CACNA1A mutation results in episodic ataxia with migrainous features without headache. Cephalalgia. 2012;32:1147–1149. doi: 10.1177/0333102412459572. [DOI] [PubMed] [Google Scholar]
- 27.Qi H, Moran MM, Navarro B, et al. All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(4):1219–1223. doi: 10.1073/pnas.0610286104. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Changeux JP. The nicotinic acetylcholine receptor: the founding father of the pentameric ligand-gated ion channel superfamily. The Journal of Biological Chemistry. 2012;287:40207–40215. doi: 10.1074/jbc.R112.407668. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Benes FM. Handbook of Experimental Pharmacology. Berlin, Germany: Springer; 2012. Nicotinic receptors and functional regulation of GABA cell microcircuitry in bipolar disorder and schizophrenia; pp. 401–417. [DOI] [PubMed] [Google Scholar]
- 30.Liu C, Su D. Nicotinic acetylcholine receptor alpha7 subunit: a novel therapeutic target for cardiovascular diseases. Frontiers of Medicine. 2012;6:35–40. doi: 10.1007/s11684-012-0171-0. [DOI] [PubMed] [Google Scholar]
- 31.Schuller HM. Regulatory role of the alpha7nAChR in cancer. Current Drug Targets. 2012;13:680–687. doi: 10.2174/138945012800398883. [DOI] [PubMed] [Google Scholar]
- 32.Cukkemane A, Seifert R, Kaupp UB. Cooperative and uncooperative cyclic-nucleotide-gated ion channels. Trends in Biochemical Sciences. 2011;36(1):55–64. doi: 10.1016/j.tibs.2010.07.004. [DOI] [PubMed] [Google Scholar]
- 33.Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiological Reviews. 2002;82(3):769–824. doi: 10.1152/physrev.00008.2002. [DOI] [PubMed] [Google Scholar]
- 34.Biel M, Zong X, Distler M, et al. Another member of the cyclic nucleotide-gated channel family, expressed in testis, kidney, and heart. Proceedings of the National Academy of Sciences of the United States of America. 1994;91(9):3505–3509. doi: 10.1073/pnas.91.9.3505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Togashi K, von Schimmelmann MJ, Nishiyama M, et al. Cyclic GMP-gated CNG channels function in Sema3A-induced growth cone repulsion. Neuron. 2008;58(5):694–707. doi: 10.1016/j.neuron.2008.03.017. [DOI] [PubMed] [Google Scholar]
- 36.Zhang Q, Zulfiqar F, Riazuddin SA, et al. Autosomal recessive retinitis pigmentosa in a Pakistani family mapped to CNGA1 with identification of a novel mutation. Molecular Vision. 2004;10:884–889. [PubMed] [Google Scholar]
- 37.Betz H, Laube B. Glycine receptors: recent insights into their structural organization and functional diversity. Journal of Neurochemistry. 2006;97(6):1600–1610. doi: 10.1111/j.1471-4159.2006.03908.x. [DOI] [PubMed] [Google Scholar]
- 38.Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiological Reviews. 2004;84(4):1051–1095. doi: 10.1152/physrev.00042.2003. [DOI] [PubMed] [Google Scholar]
- 39.Biel M, Michalakis S. Function and dysfunction of CNG channels: insights from channelopathies and mouse models. Molecular Neurobiology. 2007;35(3):266–277. doi: 10.1007/s12035-007-0025-y. [DOI] [PubMed] [Google Scholar]
- 40.Herrmann S, Layh B, Ludwig A. Novel insights into the distribution of cardiac HCN channels: an expression study in the mouse heart. Journal of Molecular and Cellular Cardiology. 2011;51:997–1006. doi: 10.1016/j.yjmcc.2011.09.005. [DOI] [PubMed] [Google Scholar]
- 41.Klueva J, Lima AD, Meis S, Voigt T, Munsch T. Hyperpolarization-activated cation current contributes to spontaneous network activity in developing neocortical cultures. Neurosignals. 2012;20:35–47. doi: 10.1159/000330813. [DOI] [PubMed] [Google Scholar]
- 42.Meurers BH, Dziewczapolski G, Bittner A, Shi T, Kamme F, Shults CW. Dopamine depletion induced up-regulation of HCN3 enhances rebound excitability of basal ganglia output neurons. Neurobiology of Disease. 2009;34(1):178–188. doi: 10.1016/j.nbd.2009.01.007. [DOI] [PubMed] [Google Scholar]
- 43.Gutman GA, Chandy KG, Grissmer S, et al. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacological Reviews. 2005;57(4):473–508. doi: 10.1124/pr.57.4.10. [DOI] [PubMed] [Google Scholar]
- 44.Richardson FC, Kaczmarek LK. Modification of delayed rectifier potassium currents by the Kv9.1 potassium channel subunit. Hearing Research. 2000;147(1-2):21–30. doi: 10.1016/s0378-5955(00)00117-9. [DOI] [PubMed] [Google Scholar]
- 45.Costigan M, Belfer I, Griffin RS, et al. Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain. 2010;133(9):2519–2527. doi: 10.1093/brain/awq195. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Hao K, Niu T, Xu X, Fang Z, Xu X. Single-nucleotide polymorphisms of the KCNS3 gene are significantly associated with airway hyperresponsiveness. Human Genetics. 2005;116(5):378–383. doi: 10.1007/s00439-005-1256-5. [DOI] [PubMed] [Google Scholar]
- 47.Hibino H, Inanobe A, Furutani K, Murakami S, Findlay I, Kurachi Y. Inwardly rectifying potassium channels: their structure, function, and physiological roles. Physiological Reviews. 2010;90(1):291–366. doi: 10.1152/physrev.00021.2009. [DOI] [PubMed] [Google Scholar]
- 48.Patil N, Cox DR, Bhat D, Faham M, Myers RM, Peterson AS. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation. Nature Genetics. 1995;11(2):126–129. doi: 10.1038/ng1095-126. [DOI] [PubMed] [Google Scholar]
- 49.Ferrer J, Nichols CG, Makhina EN, et al. Pancreatic islet cells express a family of inwardly rectifying K+ channel subunits which interact to form G-protein-activated channels. The Journal of Biological Chemistry. 1995;270(44):26086–26091. doi: 10.1074/jbc.270.44.26086. [DOI] [PubMed] [Google Scholar]
- 50.Signorini S, Liao YJ, Duncan SA, Jan LY, Stoffel M. Normal cerebellar development but susceptibility to seizures in mice lacking G protein-coupled, inwardly rectifying K+ channel GIRK2. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(3):923–927. doi: 10.1073/pnas.94.3.923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Gourraud JB, le Scouarnec S, Sacher F, et al. Identification of large families in early repolarization syndrome. Journal of the American College of Cardiology. 2013;61:164–172. doi: 10.1016/j.jacc.2012.09.040. [DOI] [PubMed] [Google Scholar]
- 52.Gabriel L, Lvov A, Orthodoxou D, et al. The acid-sensitive, anesthetic-activated potassium leak channel, KCNK3, is regulated by 14-3-3beta-dependent, protein kinase C, (PKC)-mediated endocytic trafficking. The Journal of Biological Chemistry. 2012;287:32354–32366. doi: 10.1074/jbc.M112.391458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Vandorpe DH, Morris CE. Stretch activation of the Aplysia S-channel. Journal of Membrane Biology. 1992;127(3):205–214. doi: 10.1007/BF00231508. [DOI] [PubMed] [Google Scholar]
- 54.Maingret F, Fosset M, Lesage F, Lazdunski M, Honoré E. TRAAK is a mammalian neuronal mechano-gated K+ channel. The Journal of Biological Chemistry. 1999;274(3):1381–1387. doi: 10.1074/jbc.274.3.1381. [DOI] [PubMed] [Google Scholar]
- 55.Kleger A, Liebau S. Calcium-activated potassium channels, cardiogenesis of pluripotent stem cells, and enrichment of pacemaker-like cells. Trends in Cardiovascular Medicine. 2011;21:74–83. doi: 10.1016/j.tcm.2012.03.003. [DOI] [PubMed] [Google Scholar]
- 56.Imlach WL, Finch SC, Miller JH, Meredith AL, Dalziel JE. A role for BK channels in heart rate regulation in rodents. PLoS ONE. 2010;5(1) doi: 10.1371/journal.pone.0008698.e8698 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Guo W, Xu X, Gao X, Burnstock G, He C, Xiang Z. Expression of P2X5 receptors in the mouse CNS. Neuroscience. 2008;156(3):673–692. doi: 10.1016/j.neuroscience.2008.07.062. [DOI] [PubMed] [Google Scholar]
- 58.Ryten M, Yang SY, Dunn PM, Goldspink G, Burnstock G. Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. The FASEB Journal. 2004;18(12):1404–1406. doi: 10.1096/fj.03-1175fje. [DOI] [PubMed] [Google Scholar]
- 59.Ryten M, Dunn PM, Neary JT, Burnstock G. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. Journal of Cell Biology. 2002;158(2):345–355. doi: 10.1083/jcb.200202025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Sonin D, Zhou SY, Cronin C, et al. Role of P2X purinergic receptors in the rescue of ischemic heart failure. American Journal of Physiology. 2008;295(3):H1191–H1197. doi: 10.1152/ajpheart.00577.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Feske S, Skolnik EY, Prakriya M. Ion channels and transporters in lymphocyte function and immunity. Nature Reviews Immunology. 2012;12:532–547. doi: 10.1038/nri3233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Jung SH, Ho JH. ATP stimulates mouse embryonic stem cell proliferation via protein kinase C, phosphatidylinositol 3-kinase/Akt, and mitogen-activated protein kinase signaling pathways. Stem Cells. 2006;24(12):2637–2648. doi: 10.1634/stemcells.2005-0588. [DOI] [PubMed] [Google Scholar]
- 63.Watanabe H, Iino K, Ohba T, Ito H. Possible involvement of TRP channels in cardiac hypertrophy and arrhythmia. doi: 10.2174/1568026611313030006. Current Topics in Medicinal Chemistry. In press. [DOI] [PubMed] [Google Scholar]
- 64.Takada Y, Numata T, Mori Y. Targeting TRPs in neurodegenerative disorders. doi: 10.2174/1568026611313030009. Current Topics in Medicinal Chemistry. In press. [DOI] [PubMed] [Google Scholar]
- 65.Cheng H, Feng JM, Figueiredo ML, et al. Transient receptor potential melastatin type 7 channel is critical for the survival of bone marrow derived mesenchymal stem cells. Stem Cells and Development. 2010;19(9):1393–1403. doi: 10.1089/scd.2009.0262. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.den Dekker E, Molin DGM, Breikers G, et al. Expression of transient receptor potential mRNA isoforms and Ca2+ influx in differentiating human stem cells and platelets. Biochimica et Biophysica Acta. 2001;1539(3):243–255. doi: 10.1016/s0167-4889(01)00112-4. [DOI] [PubMed] [Google Scholar]
- 67.Weick JP, Johnson MA, Zhang SC. Developmental regulation of human embryonic stem cell-derived neurons by calcium entry via transient receptor potential channels. Stem Cells. 2009;27(12):2906–2916. doi: 10.1002/stem.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Sabourin J, Antigny F, Robin E, Frieden M, Raddatz E. Activation of transient receptor potential canonical 3 (TRPC3)-mediated Ca2+ entry by A1 adenosine receptor in cardiomyocytes disturbs atrioventricular conduction. The Journal of Biological Chemistry. 2012;287:26688–26701. doi: 10.1074/jbc.M112.378588. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Haythornthwaite A, Stoelzle S, Hasler A, et al. Characterizing human ion channels in induced pluripotent stem cell-derived neurons. Journal of Biomolecular Screening. 2012;17:1264–1272. doi: 10.1177/1087057112457821. [DOI] [PubMed] [Google Scholar]
- 70.Chopra SS, Stroud DM, Watanabe H, et al. Voltage-gated sodium channels are required for heart development in zebrafish. Circulation Research. 2010;106(8):1342–1350. doi: 10.1161/CIRCRESAHA.109.213132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 71.Li GR, Sun H, Deng X, Lau CP. Characterization of ionic currents in human mesenchymal stem cells from bone marrow. Stem Cells. 2005;23(3):371–382. doi: 10.1634/stemcells.2004-0213. [DOI] [PubMed] [Google Scholar]
- 72.Jiang P, Rushing SN, Kong CW, et al. Electrophysiological properties of human induced pluripotent stem cells. American Journal of Physiology. 2010;298(3):C486–C495. doi: 10.1152/ajpcell.00251.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.House CD, Vaske CJ, Schwartz AM, et al. Voltage-gated Na+ channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Research. 2010;70(17):6957–6967. doi: 10.1158/0008-5472.CAN-10-1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Meisler MH, O’Brien JE, Sharkey LM. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. The Journal of Physiology. 2010;588(11):1841–1848. doi: 10.1113/jphysiol.2010.188482. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Arking DE, Sotoodehnia N. The genetics of sudden cardiac death. Annual Review of Genomics and Human Genetics. 2012;13:223–239. doi: 10.1146/annurev-genom-090711-163841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Davis RP, Casini S, van den Berg CW, et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation. 2012;125:3079–3091. doi: 10.1161/CIRCULATIONAHA.111.066092. [DOI] [PubMed] [Google Scholar]
- 77.Giuliano CJ, Kerley-Hamilton JS, Bee T, et al. Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochimica et Biophysica Acta. 2005;1731(1):48–56. doi: 10.1016/j.bbaexp.2005.08.006. [DOI] [PubMed] [Google Scholar]
- 78.Rybalchenko V, Ahuja M, Coblentz J, et al. Membrane potential regulates nicotinic acid adenine dinucleotide phosphate (NAADP) dependence of the pH- and Ca2+-sensitive organellar two-pore channel TPC1. The Journal of Biological Chemistry. 2012;287:20407–20416. doi: 10.1074/jbc.M112.359612. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79.Davies PA, Wang W, Hales TG, Kirkness EF. A novel class of ligand-gated ion channel is activated by Zn2+ . The Journal of Biological Chemistry. 2003;278(2):712–717. doi: 10.1074/jbc.M208814200. [DOI] [PubMed] [Google Scholar]
- 80.Kaye JA, Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Molecular and Cellular Neurosciences. 2013 doi: 10.1016/j.mcn.2013.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Nedelec S, Onteniente B, Peschanski M, Martinat C. Genetically-modified stem cells for the treatment of neurological diseases. Current Gene Therapy. 2013;4:1170–1181. doi: 10.2174/1566523211313020005. [DOI] [PubMed] [Google Scholar]
- 82.Okano H, Nakamura M, Yoshida K, et al. Steps toward safe cell therapy using induced pluripotent stem cells. Circulation Research. 2013;112:523–533. doi: 10.1161/CIRCRESAHA.111.256149. [DOI] [PubMed] [Google Scholar]